A toxin-antitoxin module as a target for antimicrobial development

Plasmid. 2010 Jan;63(1):31-9. doi: 10.1016/j.plasmid.2009.09.005. Epub 2009 Oct 1.

Abstract

The emergence and spread of pathogenic bacteria that have become resistant to multiple antibiotics through lateral gene transfer have created the need of novel antimicrobials. Toxin-antitoxin (TA) modules, which have been implicated in plasmid maintenance and stress management, are ubiquitous among plasmids from vancomycin or methicillin resistant bacteria. In the Streptococcus pyogenes pSM19035-encoded TA loci, the labile epsilon antitoxin binds to free zeta toxin and neutralizes it. When the zeta toxin is freed from the epsilon antitoxin, it induces a reversible state of growth arrest with a drastic reduction on the rate of replication, transcription and translation. However, upon prolonged zeta toxin action, the cells can no longer be rescued from their stasis state. A compound that disrupts the epsilon.zeta interaction can be considered as an attractive antimicrobial agent. Gene epsilon was fused to luc (Luc-epsilon antitoxin) and zeta to the gfp gene (zeta-GFP). Luc-epsilon or epsilon antitoxin neutralizes the toxic effect of the zeta or zeta-GFP toxin. In the absence of the antitoxin, free zeta or zeta-GFP triggers a reversible loss of cell proliferation, but the zetaK46A-GFP variant fails to block growth. Bioluminescence resonance energy transfer (BRET) assay was developed for high-throughput screening (HTS). To develop the proper controls, molecular dynamics studies were used to predict that the Asp18 and/or Glu22 residues might be relevant for epsilon.zeta interaction. Luc-epsilon efficiently transfers the excited energy to the fluorescent acceptor molecule (zeta-GFP or zetaK46A-GFP) and rendered high bioluminescence BRET signals. The exchange of Asp18 to Ala from zeta (D18A) affects Luc-epsilon.zetaD18A K46A-GFP interaction. In this study, we validate the hypothesis that it is possible to disrupt a TA module and offer a novel and unexploited targets to fight against antibiotic-resistant strains.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Antitoxins / metabolism*
  • Bacillus subtilis / cytology
  • Bacillus subtilis / drug effects
  • Biological Assay
  • Drug Design*
  • Escherichia coli / drug effects
  • Escherichia coli / metabolism
  • Luminescent Measurements
  • Microbial Sensitivity Tests
  • Microbial Viability / drug effects
  • Molecular Dynamics Simulation
  • Mutation / genetics
  • Peptides / pharmacology
  • Protein Structure, Secondary
  • Recombinant Fusion Proteins / metabolism
  • Streptococcus pyogenes / drug effects
  • Streptococcus pyogenes / metabolism
  • Toxins, Biological / metabolism*
  • Toxins, Biological / pharmacology

Substances

  • Anti-Infective Agents
  • Antitoxins
  • Peptides
  • Recombinant Fusion Proteins
  • Toxins, Biological